A new study published today in the journal Molecules finds that cannabidiol (CBD) enhances the cancer-cell-killing effects of an experimental anticancer compound while reducing its toxicity in kidney-derived cells, suggesting that CBD may influence how different types of cells respond to the same drug.
The study, conducted by researchers from Poznan University of Life Sciences and other institutions in Poland, examined how CBD interacts with salinomycin, a compound traditionally used in veterinary medicine that has attracted scientific interest for its potential anticancer properties. Although salinomycin has demonstrated activity against cancer cells in previous research, its toxicity has limited its potential medical applications.
Researchers tested salinomycin alone and in combination with CBD across three human cell lines: HEK-293 kidney-derived cells, HepG2 liver cancer-derived cells and SH-SY5Y neuroblastoma-derived cells. They used two CBD concentrations, 1.56 and 3.125 micrograms per milliliter, that were not toxic to the cells when administered alone.
The results revealed a notable difference in how the cells responded to the combination. In both cancer-derived cell lines, adding CBD increased salinomycin’s cytotoxic effects, resulting in greater cellular damage and more pronounced cell death than treatment with salinomycin alone.
In contrast, the kidney-derived cells experienced reduced toxicity when CBD was added. Researchers observed higher concentrations of salinomycin were needed to produce comparable toxic effects, indicating that CBD provided a degree of protection against the compound’s damaging effects in this particular cell line.
The researchers also examined oxidative stress, a process involving reactive oxygen species (ROS) that can contribute to cellular damage. CBD reduced ROS production in the kidney-derived cells while increasing it in the two cancer-derived cell lines, providing additional evidence that its effects depend on the type of cell being studied.
To assess these differences, the research team used multiple laboratory methods measuring mitochondrial and lysosomal activity, cell membrane integrity, DNA synthesis and other indicators of cellular health. The findings consistently showed that CBD altered salinomycin’s toxicity differently depending on the cell line.
The distinction is particularly relevant because one of the challenges in developing anticancer medications is finding compounds that effectively destroy cancer cells without causing excessive damage to other tissues. The findings raise the possibility that CBD could help researchers better understand how to influence the selectivity of certain experimental anticancer compounds.
However, the study was conducted entirely in laboratory-grown cells rather than animals or human patients. The researchers emphasized that the kidney-derived cells were immortalized and cannot be considered equivalent to normal kidney tissue, meaning the results do not establish that CBD would protect healthy organs during cancer treatment.
The findings provide a basis for additional research into CBD’s interactions with experimental anticancer drugs, particularly whether its ability to increase toxicity in certain cancer-derived cells while reducing it in other cell types can be reproduced in more advanced biological models.
